Kim Forest Enterprise Co., Ltd. (TPE:6645)
13.05
+0.20 (1.56%)
Aug 19, 2026, 10:46 AM CST
Kim Forest Enterprise Revenue
Kim Forest Enterprise had revenue of 154.78M TWD in the quarter ending June 30, 2026, with 23.19% growth. This brings the company's revenue in the last twelve months to 599.63M, up 17.17% year-over-year. In the year 2025, Kim Forest Enterprise had annual revenue of 549.14M with 9.49% growth.
Revenue (ttm)
599.63M
Revenue Growth
+17.17%
P/S Ratio
1.29
Revenue / Employee
n/a
Employees
58
Market Cap
775.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 549.14M | 47.62M | 9.49% |
| Dec 31, 2024 | 501.53M | 86.52M | 20.85% |
| Dec 31, 2023 | 415.01M | -255.58M | -38.11% |
| Dec 31, 2022 | 670.59M | 69.92M | 11.64% |
| Dec 31, 2021 | 600.67M | 297.78M | 98.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.29B |
| DIVA Laboratories | 894.67M |
| Genetics Generation Advancement | 614.42M |
| Welgene Biotech | 398.92M |
| Sofiva Genomics | 379.21M |
| Pharmigene | 187.88M |
| Puriblood Medical | 80.54M |